J. Goldman & CO LP Nuvalent, Inc. Transaction History
J. Goldman & CO LP
- $3.21 Billion
- Q3 2024
A detailed history of J. Goldman & CO LP transactions in Nuvalent, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 2,700 shares of NUVL stock, worth $223,155. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,700
Previous 6,456
58.18%
Holding current value
$223,155
Previous $489,000
43.56%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding NUVL
# of Institutions
209Shares Held
59.5MCall Options Held
450KPut Options Held
619K-
Deerfield Management Company, L.P. (Series C) New York, NY20MShares$1.65 Billion38.02% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5MShares$413 Million18.43% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.13MShares$342 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$250 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.98MShares$246 Million7.96% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.55B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...